AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AstraZeneca has launched a Phase 3 clinical study titled ‘DESTINY-Biliary Tract Cancer-01’ to evaluate the efficacy and safety of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig against the standard-of-care (SoC) treatment in patients with advanced HER2-expressing biliary tract cancer (BTC). The study aims to determine whether the experimental drugs can provide a better treatment alternative to the current SoC, which includes Gemcitabine, Cisplatin, and Durvalumab.
The study tests two experimental interventions: T-DXd combined with Rilvegostomig and T-DXd monotherapy. These drugs are designed to target HER2-expressing cancer cells more effectively than existing treatments.
The study follows an interventional design with randomized allocation and a parallel intervention model. It is an open-label study, meaning both researchers and participants know which treatment is being administered. The primary purpose of the study is treatment-focused.
The study began on August 12, 2024, with an estimated primary completion date yet to be announced. The most recent update was submitted on August 18, 2025. These dates are crucial for tracking the study’s progress and assessing its potential impact on the market.
This study could significantly influence AstraZeneca’s stock performance and investor sentiment, especially if the results show a marked improvement over current treatments. The outcome may also affect competitors in the oncology sector, as successful results could shift market dynamics in favor of AstraZeneca.
The study is ongoing, with further details available on the ClinicalTrials portal.